ELEVATED SERUM GAMMA-GLUTAMYLTRANSFERASE IS AN ADVERSE PROGNOSTIC FACTOR IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE

被引：0
|
作者：
Takemura, Kosuke
Ito, Masaya
Nakanishi, Yasukazu
Kataoka, Madoka
Sakamoto, Kazumasa
Suzuki, Hiroaki
Iida, Noriyuki
Tobisu, Ken-ichi
Koga, Fumitaka
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 201卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP28-11
引用
收藏
页码：E407 / E408
页数：2
相关论文
共 50 条
  • [41] Prognostic Significance of the Serum Marker Gamma-Glutamyltransferase in female Patients with Vulvar Cancer
    Rahhal-Schupp, J.
    Grimm, C.
    Aust, S.
    Pecnik, P.
    Joura, E.
    Reinthaller, A.
    Polterauer, S.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2012, 72 (04)
  • [42] Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer
    Yamasaki, Mutsushi
    Yuasa, Takeshi
    Yamamoto, Shinya
    Hayashi, Tatsuro
    Ogawa, Masahiro
    Sakura, Mizuaki
    Masuda, Hitoshi
    Fukui, Iwao
    Yonese, Junji
    ANTICANCER RESEARCH, 2016, 36 (01) : 361 - 365
  • [43] Castration-Resistant Prostate Cancer: Enzalutamide better than Placebo
    Lorenz, Judith
    Kretschmer, Alexander
    AKTUELLE UROLOGIE, 2019, 50 (01) : 12 - 13
  • [44] Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
    El-Amm, Joelle
    Patel, Nihar
    Freeman, Ashley
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 235 - 245
  • [45] Enzalutamide - a new agent for treatment of castration-resistant prostate cancer
    Wysocki, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (05): : 186 - 190
  • [46] COMBINATION OF INDOMETHACIN AND ENZALUTAMIDE TO TREAT CASTRATION-RESISTANT PROSTATE CANCER
    Liu, Chengfei
    Lou, Wei
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher
    Parikh, Mamta
    White, Ralph deVere
    Dall'Era, Marc
    Gao, Allen
    JOURNAL OF UROLOGY, 2018, 199 (04): : E694 - E694
  • [47] Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer
    Mori, Keiichiro
    Egawa, Shin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2021, 79 (03) : 430 - 431
  • [48] Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer
    Mason, Malcolm
    EUROPEAN UROLOGY, 2018, 74 (06) : 845 - 845
  • [49] Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Schultz, Neil M.
    O'Day, Ken
    Sugarman, Rebecca
    Ramaswamy, Krishnan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 538 - 549
  • [50] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
12345